LifeCell Corp. has begun a pilot clinical study of its AlloDermdermal tissue graft for treatment of venous stasis ulcers. This isthe second indication for the freeze-dried cadaver dermis to betested in clinicals.

LifeCell (NASDAQ:LIFC) announced Friday that the study isunder way at the University of South Alabama in Mobile todetermine "AlloDerm's 'take' to the ulcer wound and its abilityto expedite healing by providing a better dermal foundation forthe patient's own epidermal cells."

AlloDerm is already in clinical trials for use in the treatment ofthird-degree burns to reduce the amount of a patient's ownskin required for grafting. LifeCell of The Woodlands, Texas,said it also plans to conduct studies of AlloDerm as a treatmentfor surgical scars, diabetic ulcers and decubitus ulcers.

(c) 1997 American Health Consultants. All rights reserved.